Paul Adriaan Jan, Baron Janssen (12 September 1926 – 11 November 2003) was a Belgian physician. He was the founder of Janssen Pharmaceutica, a pharmaceutical company with over 20,000 employees[1] which is now a subsidiary of Johnson & Johnson.
Early life and education
Paul Janssen was the son of Constant Janssen and Margriet Fleerackers.
During his military service and until 1952, he worked at the Institute of Pharmacology of the University of Cologne. After he returned to Belgium, he worked part time at the University of Ghent Institute of Pharmacology and Therapeutics, headed by Corneille Heymans, who had won the Nobel Prize for medicine in 1938.[citation needed]
With a loan of fifty thousand Belgian francs received from his father, Janssen founded his own research laboratory in 1953. That same year, he discovered ambucetamide, an antispasmodic found to be particularly effective for the relief of menstrual pain.[4]
In 1956, Janssen received his habilitation in pharmacology with pro venia legendi ("permission to lecture") designation for his thesis on Compounds of the R 79 type. He left the university and established what would become Janssen Pharmaceutica.[citation needed]
In 1959, Janssen synthesized the potent opioid fentanyl based on SAR studies of meperidine.[citation needed] In the 1970s, he would improve upon the potency of fentanyl with the synthesis of Carfentanil.
In 1985, Janssen Pharmaceutical became the first Western pharmaceutical company to establish a factory in China.[10] In 1995, together with Paul Lewi, he founded the Center for Molecular Design, where he and his team[11] used a supercomputer to search candidate molecules for potential AIDS treatments.[12][13]
Janssen died in Rome in 2003, while attending the celebration of the 400th anniversary of the founding of the Pontifical Academy of Sciences, of which he had been a member since 1990.[14]
^I. Oransky, Paul Janssen, The Lancet, Volume 363, Issue 9404, Pages 251–251
^B. Granger, S. Albu, The Haloperidol Story, Annals of Clinical Psychiatry (after 1 January 2004), Volume 17, Number 3, Number 3/July–September 2005, pp. 137–140(4)
^Lopez-Munoz, Francisco; Alamo, Cecilio (2009). "The Consolidation of Neuroleptic Therapy: Janssen, the Discovery of Haloperidol and Its Introduction into Clinical Practice". Brain Research Bulletin. 79 (2): 130–141. doi:10.1016/j.brainresbull.2009.01.005. PMID19186209. S2CID7720401.
^Yven Van Herrewege, Guido Vanham, Jo Michiels, Katrien Fransen, Luc Kestens, Koen Andries, Paul Janssen, and Paul Lewi, A Series of Diaryltriazines and Diarylpyrimidines Are Highly Potent Nonnucleoside Reverse Transcriptase Inhibitors with Possible Applications as Microbicides, Antimicrob Agents Chemother. 2004 October; 48(10): 3684–3689
Lewi, Paul J., Successful Pharmaceutical Discovery: Paul Janssen's Concept of Drug Research, R&D Management, Vol. 37, Issue 4, pp. 355–362, September 2007.
van Gestel S, Schuermans V, Thirty-three years of drug discovery and research with Dr. Paul Janssen, Drug Development Research, Volume 8, Issue 1–4, pp. 1–13.
Geerdt Magiels; Joos Horsten (2004). Paul Janssen: pionier in farma en in China. Houtekiet. ISBN9789052408279.
.JPG)
